On January 7, 2026, The United Laboratories Animal Healthcare received three new veterinary drug registration certificates from the Ministry of Agriculture and Rural Affairs. All approved products focus on the pet sector, including the antiparasitic active ingredient fluralaner (Category II), its formulation fluralaner chewable tablets (Category II), and prednisolone tablets (Category V). This marks comprehensive, multi-level breakthroughs in the company's pet drug R&D, elevating its R&D strength and quality control capabilities to a new level.